Fact based stock research
Sam Chun Dang Pharm. (KOSDAQ:A000250)


Sam Chun Dang Pharm. stock research in summary


Sam Chun Dang Pharm. shares are more expensive than other comparable stocks. While they are safely financed, they are poor value, and show below average growth. We recommend evaluating whether the future of the company Sam Chun Dang Pharm. is really as positive as the high price of the shares suggests. If you come to the conclusion that the future for this company is only average, that could be a reason to sell this share.

Latest Obermatt Ranks

Country South Korea
Industry Pharmaceuticals
Size class Small

September 30, 2021. Stock data may be delayed. Login to get the most recent research.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Sam Chun Dang Pharm. from September 30, 2021.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.